HB3001 — INS CD-CANCER SCREENINGS
Last action — Added Co-Sponsor Rep. Amy Briel
-
1Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill has been introduced in the House. Introduced February 06, 2025. It must pass committee before a floor vote.
Next likely step: a committee referral and hearing.
Odds of enactment
Low chanceBased on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
Introduced
Current position in the legislative process.
-
2 sponsors
1 primary, 1 co-sponsors signed on.
-
Bipartisan support
Sponsored across 2 parties (1 R · 1 D) — cross-party backing.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
Summary
Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
Bill Text
We don't have the full text on file for this bill yet.
Read HB3001 on the official Illinois source →Action History
-
Added Co-Sponsor Rep. Amy Briel
-
Rule 19(a) / Re-referred to Rules Committee
-
To Insurance Main Subcommittee
-
Assigned to Insurance Committee
-
Referred to Rules Committee
-
First Reading
-
Filed with the Clerk by Rep. Norine K. Hammond
Sponsors
- Norine K. Hammond · Primary
- Amy Briel · Cosponsor
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 1 co-sponsors · 181 not signed on
Sponsors (1)
- Norine K. Hammond Republican
Co-sponsors (1)
- Amy Briel Democrat
Not signed on (181)
181 members have not signed on to this bill.
Show all 181 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HB3001 do?
- Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
- Who sponsors HB3001 ?
- HB3001 is sponsored by Norine K. Hammond (Republican) and Amy Briel (Democrat).
- What is the current status of HB3001 ?
- This bill has been introduced in the House. Introduced February 06, 2025. It must pass committee before a floor vote.
- Where can I track HB3001 ?
- Track HB3001 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HB3001
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HB3001
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →